2021
DOI: 10.5455/medarh.2021.75.101-108
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of the Genetic Association and Expressions of Notch-2 /Jagged-1 in Patients with Type 2 Diabetes Mellitus

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 44 publications
0
4
0
Order By: Relevance
“…Several studies have confirmed the association between the increased Notch 1, 3, and 4 expressions in renal tissue and the development of diabetic nephropathy [ 17 , 42 ]. Moreover, one recent study has defined Notch2 and Jagged1 as possible biomarkers for distinguishing moderate and severe stages of diabetic nephropathy [ 43 ]. Although previous studies strongly support the role of Notch signaling in the development of renal fibrosis, they did not establish the specific ligand and receptor responsible for fibrosis advancement in different pathologies, including DN.…”
Section: Discussionmentioning
confidence: 99%
“…Several studies have confirmed the association between the increased Notch 1, 3, and 4 expressions in renal tissue and the development of diabetic nephropathy [ 17 , 42 ]. Moreover, one recent study has defined Notch2 and Jagged1 as possible biomarkers for distinguishing moderate and severe stages of diabetic nephropathy [ 43 ]. Although previous studies strongly support the role of Notch signaling in the development of renal fibrosis, they did not establish the specific ligand and receptor responsible for fibrosis advancement in different pathologies, including DN.…”
Section: Discussionmentioning
confidence: 99%
“…CXCL5 has been shown to be activated abortion [56]. [85], NOTCH2 [86], LRP1 [87], CLU (clusterin) [88], FCN1 [89], CDKN1A [90], SMAD3 [91], HLA-E [92], PTPRC (protein tyrosine phosphatase receptor type C) [93], MYH9 [94], JAK3 [95], IL6R [96], TIMP1 [97], DOCK8 [98], TNFRSF1B [99], ITGAL (integrin subunit alpha L) [100], CD47 [101], RARA (retinoic acid receptor alpha) [102], DGKD (diacylglycerol kinase delta) [103], PLEK (pleckstrin) [104], PREX1 [105], BSCL2 [106], PANX1 [107], IRF7 [108] [116] were revealed to be expressed in diabetes mellitus, but these genes might be novel targets for GDM. SIX1 [117], GREM1 [118], GHRHR (growth hormone releasing hormone receptor) [119], GPR37L1 [120], CYP2J2 [121], AQP4 [122], ROS1 [123], LBP (lipopolysaccharide binding protein) [124], SGCD (sarcoglycan delta) [133], PTHLH [134], FAP (fibroblast activation protein alpha) [135], THSD7A [136], SHROOM3 [137], ETV1 [138], CYP24A1 [139], SLIT2 [140], GJC1 [141], PPARGC1A [142], TRPM3 [143], IGF1 [144], TRPV6 [145], TLR3 [146], BMP7 [147], DSG2 [148], POSTN (periostin) [149], ENOX1…”
Section: Discussionmentioning
confidence: 99%
“…Pathways include hemostasis [57], neutrophil degranulation [58], immune system [59] and cytokine signaling in immune system [60] are responsible for progression of GDM. LGR5 [61], GREM1 [62], GLRA3 [63], NEUROD4 [64], CYP2J2 [65], KCNH6 [66], LBP (lipopolysaccharide binding protein) [67], CXCL14 [68], RGN (regucalcin) [69], NPY2R [70], SERPINB13 [71], WNT5A [72], EDA (ectodysplasin A) [73], HSD11B2 [74], ACVR1C [75], NEUROD1 [76], SLIT2 [77], PPARGC1A [78], IGF1 [79], OSR1 [80], CYP46A1 [81], TLR3 [82], BMP7 [83], SELP (selectin P) [84], HLA-A [85], NOTCH2 [86], LRP1 [87], CLU (clusterin) [88], FCN1 [89], CDKN1A [90], SMAD3 [91], HLA-E [92], PTPRC (protein tyrosine phosphatase receptor type C) [93], MYH9 [94], JAK3 [95], IL6R [96], TIMP1 [97], DOCK8 [98], TNFRSF1B [99], ITGAL (integrin subunit alpha L) [100], CD47 [101], RARA (retinoic acid receptor alpha) [102], DGKD (diacylglycerol kinase delta) [103], PLEK (pleckstrin) [104], PREX1 [105], BSCL2 [106], PANX1 [107], IRF7 [108], NOTCH1 [109], STIM1 [110], TRIM13 [111], LRBA (LPS responsive beige-like anchor protein) [112], CXCR4 [113], MDM4 [114], MYO9B [115] and PDE5A [116] were revealed to be expressed in diabetes mellitus, but these genes might be novel targets for GDM. SIX1 [117], GREM1 [118], GHRHR (growth hormone releasing hormone receptor) [119], GPR37L1 [120], CYP2J2 [121], AQP4 [122], ROS1 [123], LBP (lipopolysaccharide binding protein) [124], SGCD (sarcoglycan delta) [125], CXCL14 [126], RGN...…”
Section: Discussionmentioning
confidence: 99%
“…In DKD, the Notch signaling pathway is significantly activated, mediating glomerular function, podocyte damage, and tubular interstitial fibrosis ( Zhang et al, 2021 ; Li et al, 2022 ). A randomized controlled clinical study showed that elevated Notch2 and Jagged1 gene expression levels were associated with DKD in humans and could serve as potential biomarkers for DKD ( Al-Awaida et al, 2021 ). In a study of renal biopsies in patients with DKD and animal models of DKD, it was found that interaction of the Notch signaling pathway with the NF-κB signaling pathway in macrophages promoted polarization of the macrophages and exacerbated the inflammatory response, fibrosis, and necrosis of the intrinsic cells in the kidneys.…”
Section: Specific Cell Types and Associated Signaling Pathways For Dkdmentioning
confidence: 99%